Your browser doesn't support javascript.
loading
Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study.
Malik, Ali O; Chen, Hungta; Tang, Fengming; Chan, Paul S; Cooper, Andrew; Gomes, Marίlia B; Hejjaji, Vittal; Ji, Linong; Khunti, Kamlesh; Kosiborod, Mikhail; Nicolucci, Antonio; Peri-Okonny, Poghni A; Shestakova, Marina V; Vora, Jiten; Watada, Hirotaka; Arnold, Suzanne V.
Afiliação
  • Malik AO; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA. Electronic address: aomalik@saint-lukes.org.
  • Chen H; AstraZeneca, Gaithersburg, MD, USA.
  • Tang F; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
  • Chan PS; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
  • Cooper A; AstraZeneca, Cambridge, UK.
  • Gomes MB; Rio de Janeiro State University, Rio de Janeiro, Brazil.
  • Hejjaji V; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
  • Ji L; Peking University People's Hospital, Beijing, China.
  • Khunti K; University of Leicester, Leicester, UK.
  • Kosiborod M; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA; The George Institute for Global Health and University of New South Wales, Sydney, Australia.
  • Nicolucci A; Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
  • Peri-Okonny PA; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
  • Shestakova MV; Endocrinology Research Center, Diabetes Institute, Moscow, Russian Federation.
  • Vora J; Royal Liverpool University Hospital, Liverpool, UK.
  • Watada H; Graduate School of Medicine, Juntendo University, Tokyo, Japan.
  • Arnold SV; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
Indian Heart J ; 74(5): 398-405, 2022.
Article em En | MEDLINE | ID: mdl-35926587
ABSTRACT

BACKGROUND:

We sought to describe global patterns in achievement of risk factor control for primary prevention in patients with T2D and explore the association of country's GNI/capita with risk factor control.

METHODS:

The DISCOVER study is a prospective, observational study of patients with T2D from 38 countries enrolled at initiation of second-line glucose-lowering therapy. We examined achievement of risk factor control (glycosylated hemoglobin <7%, blood pressure <140/90 mmHg, prescription of a statin) at 3 years among those without optimal control at baseline. Countries were stratified by gross national income (GNI)/capita, from 2017). We examined the impact of country GNI/capita with achievement of risk factor control.

FINDINGS:

Our cohort included 9613 patients with T2D and without baseline cardiovascular disease (mean age 57.2 ± 8.7 years, 47.9% women). At baseline, 6354/7646 patients (83.1%) had suboptimal glucose control, 3449/9200 patients (37.5%) had suboptimal BP control, and 2800/4221 patients (66.7%) were not on an appropriate statin (sample sizes differed due to missing covariate data). Optimal control at 3 years of follow-up was achieved in 41% (glucose), 56% (blood pressure), and 29% (statins) of patients. There was significant variability in achievement of risk factor control across countries but no association between country GNI/capita with achievement of risk factor control (p > 0.08 for all).

INTERPRETATION:

In a global, prospective study of patients with T2D, we found that cardiovascular risk factor control achievement was suboptimal despite 3 years of follow-up in specialized health care systems. Neither country-level nor patient-level socioeconomic factors fully explained this finding.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Health_economic_evaluation / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Health_economic_evaluation / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article